Clinical Trial

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

Study acronym: DÁLIA
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 2, 2023 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of LID104 in the treatment of type 2 diabetes mellitus.
Trial Details
NCT Number NCT05886088
Lead Sponsor EMS
Conditions Type 2 Diabetes Mellitus
Enrollment 597 participants
Start Date 2024-02
Primary Completion 2026-05 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2023-06-02